Last Updated: December 22nd, 2025
We support successful product launches in the Middle East by aligning market access strategy, localized economic evidence, and launch sequencing. Through model adaptation, HTA landscape assessment, and affiliate collaboration, we identified Saudi Arabia as a priority early launch market. This supported a streamlined, market-ready entry aligned with local requirements.
How Technical Expertise Supports Launch Planning
Our team advises on market access strategy and launches sequencing for hematology products approaching commercialization in the Middle East, ensuring plans are grounded in technical rigor and regional access realities.
The Market Access Landscape Assessment
Emerging HTA entities, shaped by the Vision 2030 plan, align with evidence-based expectations, review pathways, and key commercial considerations that influence access and reimbursement decisions.
Economic Models Adaption Locally
Global economic models incorporate local epidemiology, cost inputs, and relevant comparators to reflect the Saudi Arabian context. Differences in treatment pathways, sequencing, and positioning ensure the relevance of decisions.
Integration of Regional Insights
Affiliate teams across Middle Eastern markets are engaging to capture country-specific insights, validate assumptions, and ensure strategies reflect local market dynamics.
How Our Practical Agility Keeps Teams Ahead
Our lean operating model enables close collaboration, rapid mobilization of expertise, and efficient delivery, all without unnecessary complexity, thereby supporting timely decision-making and execution.
Launch Sequencing Framing
Addressable patient populations and reimbursed pricing potential are quantified while considering cross-HTA factors such as international reference pricing. These insights support the prioritization and sequencing of launches, with Saudi Arabia identified as an early entry market.
Affiliate Engagement Supporting Execution
Workshops with regional affiliate teams facilitate alignment on evidence needs, market opportunities, and access strategies.
Customer Testimonies
Maintaining Launch Momentum
Beyond initial planning, successful launches require momentum to be maintained as market conditions evolve. We help teams stay aligned as evidence and priorities evolve, supporting consistent decisions across markets.
Our Expert Support
If you are developing a launch strategy in the Middle East, our team can support evidence, access, and execution planning. We help align strategy with regional requirements and launch goals. Connect with our experts.
Preparing for market entry in the Middle East?
Meet our Outcomes Research Team
Holly Guy
Executive Director
She brings extensive HEOR experience across the product lifecycle, with 30+ successful HTA submissions to NICE, SMC, AWMSG, and other European agencies. She has represented pharma companies at appraisal committee meetings and led the team behind the first new advanced ovarian cancer treatment approved in nearly 20 years.
FAQs on Early Modeling for Price Potential & HTA
What is required for successful market access launches in the Middle East?
Successful launches require early market access planning, alignment with local HTA expectations, and adaptation of global evidence to country-specific decision frameworks.How early should companies plan for a Middle East product launch?
Market access planning should begin well ahead of launch to allow time for evidence alignment, pricing considerations, and informed launch sequencing across markets.How do HTA processes affect Middle East launch strategy?
HTA processes influence evidence requirements, review timelines, and access pathways, making early understanding critical for effective launch planning in the region.How can biopharma teams prioritize Middle East markets for launch?
Market prioritization is informed by access readiness, pricing potential, and local requirements, helping teams sequence launches to reduce risk and support timely entry.